Skip to main content

Critical quality events-QP




Critical quality events-QP

EU Guidelines for Good Manufacturing Practice for Medicinal Products for
Human and Veterinary Use - Annex 16: Certification by a Qualified Person
and Batch Release

Quality Event: The event occurred during manufacturing / analysis of batch
/ lot or event occurred during the batch / lot is in the distribution system or
as a market feedback which is likely to have potential impact on finished
product

Qualified Person (QP): QP is the person responsible for ensuring that
each individual batch has been manufactured and checked in compliance
with laws in force in the Member State where certification takes place, in
accordance with the requirements of the marketing authorization (MA) and
with Good Manufacturing Practice (GMP)

Periodic Events Notification-
Quality events summary report shall be prepared on quarterly basis
1.    Incidents-
Incidents which have a systemic effect:
· Any validation / qualification failure which have a direct impact on product quality.
· Incidents related to Cleaning validation failure.
· Any other deviations which will have an impact on product quality.


2.    Change Control-
Change control impacting systems:
· HVAC, WFI system, pure steam generation system, Purified water system, process equipment which were not reported as a batch specific event.
· Related to facility changes which have a direct impact on product quality, like
o Changes in Grade A, B or C areas of manufacturing.
o Changes in Grade A, B areas of microbiology.
· Any changes in product specification or validated parameters, which were not reported as batch specific event.

3.    Quarterly EMP/ Water trend summary-
Only excursions to be reported. If there is no excursion during this period, report as “No Out of limit results reported”.

4.    Stability failure/ Critical Market complaint-
In case of stability failure in commercialized products, QP shall be informed on immediate basis for further actions, in line with the technical agreements with customers. However, in periodic events notification, a summary shall be provided.

5.    Adverse report finding-
Any adverse report related to the product quality complaint to be reported


6.    Any regulatory actions-

To brief about any regulatory actions like, critical observations, warning letter issued to the facility, import alert raised

7.    Media fill positives-
Notification timeline shall be as defined in the relevant technical or quality agreements
8.    Sterility test failure-
Any sterility test failure related to that particular line in this period which was not reported as batch specific event.

Labels:

Comments

Post a Comment

Popular posts from this blog

Change Management System

US Market (Supplement): Post approval drug manufacturing supplement for NDAs/ ANDA submitted to FDA for Major or Moderate manufacturing change. Major change - If a manufacturing change is considered to be major, an applicant must submit and receive FDA approval of a prior-approval supplement (PAS) before the drug product made with the change is distributed. Moderate change- If a manufacturing change is considered to be moderate, an applicant must submit a supplement at least 30 days before the drug product is distributed (a CBE-30 supplement) or, in some cases, submit a supplement at the time of distribution (a CBE-0 supplement).  “CBE” means “changes-being-effected”. Post manufacturing supplement - 1. CBE 0 (Change being effected before 00 days): 2. CBE 30 (Change being effected before 30 days): 3. PAS (Prior approval supplement): EUROPE Market (Variation): A variation to the terms of a marketing authorization is an amendment to the contents of the docume...
Post a Comment
Read more

Air velocity measurement and correlation to smoke study

Air velocity measurement As part of risk assessment this evaluation should also consider the selection of locations for the critical control points for monitoring air velocity as well as viable and non-viable particles. 1. Problem Statement- Where should airflow velocity measurements be taken with respect to a filling line or other aseptic processing areas? Recommendation Airflow velocity measurements should be taken at locations where meaningful and reproducible results can be obtained. This is typically at a distance of 6 inches from the filter face . Rationale for Recommendation The primary reason for airflow velocity measurements in unidirectional airflow areas (e.g., areas where product, product contact packaging components, and product contact surfaces are exposed) is to assure there is adequate airflow to protect the materials from external airborne contamination . Accurate measurements can be taken and changes over time detected when airflow velocities are e...
Post a Comment
Read more

AMFSS (Aseptic Media Fill Simulation Study)

Guidelines - 1. PDA Technical report No.: 22- "Process Simulation Testing for Aseptically Filled Products". 2. PDA Technical report No.: 44- "Quality Risk Management for Aseptic Processes". 2. PIC'S (Pharmaceutical inspection convention or Pharmaceutical inspection co-operation scheme) 3. USFDA Guidance to industry (Sep/2004)- "Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice, September 2004" 4. European guideline to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use, Annex 1: Manufacture of Sterile Medicinal Products, (corrected version) November 2008. Aseptic Media fill Simulation Study necessary to- *Qualify the process line *Qualify the personal *Qualify the container- closure system Media fills may be used to: 1. Support new or revised aseptic processes are operating under the desired state of control. 2. Periodically confirm the aseptic pr...
Post a Comment
Read more